Virocan Therapeutics Private Limited, a active private limited company, was established on 18 August 2005 in Guntur, Andhra Pradesh, India. Engaging in chemical products within the chemicals sector, it holds CIN: U24239AP2005PTC047169. Registered under ROC Roc Vijayawada. it is unlisted. It has an authorized capital of ₹4.90 M and a paid-up capital of ₹4.90 M.
It upholds a compliant status. Its leadership includes Donald Willard Weaver (Director), Jose Edson Silva Pontes (Director), Rajesh Dachepalli (Director). Past directors included Donald Willard Weaver, Ramesh Babu Batchu, Batchu Kiran Kumar. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at Nh-5, Edulapalem, Prathipadu, Guntur, Andhra Pradesh, 522019.
U24239AP2005PTC047169
047169
18 August 2005
₹4.90 M
₹4.90 M
Roc Vijayawada
Unlisted
Active
Explore comprehensive insights into Virocan Therapeutics Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Donald Willard Weaver | Director | 16 Apr 2012 | Current |
| Jose Edson Silva Pontes | Director | 20 Jul 2014 | Current |
| Rajesh Dachepalli | Director | 05 Oct 2018 | Current |
| Sreenivasa Rao Rao Batchu | Director | 21 Aug 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 02 Jul 2014 | Past |
| Pramod Abcsdd | Additional Director | 02 Jul 2014 | Past |
| Pramod Abcsdd | Director | 12 Jan 2017 | Past |
| Pramod Abcsdd | Additional Director | 06 Jan 2016 | Past |
| Pramod Abcsdd | Director | 14 Sep 2018 | Past |
| Pramod Abcsdd | Manager | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Virocan Therapeutics Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 46.1% increase in profit. The company's net worth observed a substantial decline by a decrease of 13.23%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2017, Virocan Therapeutics had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Virocan Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Virocan Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Virocan Therapeutics's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Virocan Therapeutics Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was recorded as a recent event.
Progress on Sreenivasa Rao Rao Batchu was appointed as a Director was appointed as a Director on 21 Aug 2025 & has been associated with this company since 4 months 24 days . was documented.
The activity Virocan Therapeutics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Vijayawada. was completed.
The activity Rajesh Dachepalli was appointed as a Director was appointed as a Director on 05 Oct 2018 & has been associated with this company since 7 years 3 months . was completed.
Jose Edson Silva Pontes was appointed as a Director was appointed as a Director on 20 Jul 2014 & has been associated with this company since 11 years 5 months . was recorded as a recent event.
The activity Donald Willard Weaver was appointed as a Director was appointed as a Director on 16 Apr 2012 & has been associated with this company since 13 years 8 months . was completed.
The CIN of Virocan Therapeutics Private Limited is U24239AP2005PTC047169.
Virocan Therapeutics Private Limited is headquartered at Nh-5, Edulapalem, Prathipadu, Guntur, Andhra Pradesh, 522019.
Virocan Therapeutics Private Limited was incorporated on 18 August 2005.
The current directors of Virocan Therapeutics Private Limited are
The primary industry of Virocan Therapeutics Private Limited is Chemicals.
Virocan Therapeutics Private Limited is unlisted.
The authorized capital of Virocan Therapeutics Private Limited is ₹4.90 M, and the paid-up capital is ₹4.90 M.
The compliance status of Virocan Therapeutics Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX